PoreWise

One finding · Human trial · 2007

Study title

The clinical anti-aging effects of topical kinetin and niacinamide in Asians: a randomized, double-blind, placebo-controlled, split-face comparative trial

Kind of evidence
Human trial 2007 · 52 people · Taiwanese subjects · PMID 18047609
Measured outcome
Skin effect
Year
2007
Who was studied
52 Taiwanese subjects
Sample size
52
Measured outcome
In a randomized, double-blind, placebo-controlled split-face trial of 52 Taiwanese subjects, 4% niacinamide alone significantly reduced instrument-measured pore counts at week 8, and 4% niacinamide with 0.03% kinetin produced persistent significant reductions in pore, spot, wrinkle and evenness counts at weeks 8 and 12.
Certainty
Moderate
Who was measured
Instrument-measured facial pore counts over 8-12 weeks.
Study limits
The niacinamide-group showed significant pore reduction at week 8; 'pore counts' is an instrument parameter.

Where it comes from

PMID 18047609

Ingredients it was measured on

Skin concerns studied

Other findings on the same ingredient or concern

  1. Skin effect
    Evaluation of anti-wrinkle effects of a novel cosmetic containing niacinamide

    In a randomized, placebo-controlled split-face study of 30 healthy Japanese women, a cosmetic containing 4% niacinamide reduced the skin-surface average roughness (Ra) value significantly more than the niacinamide-free control site after 8 weeks (P<0.05).

    Human trial · 2008 · 30 people · healthy Japanese women with wrinkles in the eye areas · Skin-surface roughness measured by replica profilometry (Ra). · Measured at the eye area on a photoaged/wrinkle cohort; the endpoint is surface roughness.

    PMID 19017042

  2. Skin effect
    An Investigator-Blinded, Randomized Trial of a Broad-Spectrum Sunscreen Containing Sclareolide and Niacinamide for the Prevention of Post-inflammatory Hyperpigmentation in Skin of Color

    In 20 people with Fitzpatrick skin types IV-V, a broad-spectrum sunscreen containing sclareolide and niacinamide significantly prevented experimentally induced post-inflammatory hyperpigmentation: in stripped, exposed zones the protected skin improved by +5.96 ITA degrees versus -9.88 in unprotected skin (net protection about 16 ITA degrees, p < 0.001).

    Human trial · 2026 · 20 people · participants with Fitzpatrick skin types IV-V · People with darker skin phototypes (IV-V) prone to post-inflammatory hyperpigmentation, applying the sunscreen daily for 20 days under UV and visible-light exposure. · Small sample (20), within-subject controlled model of experimentally induced pigmentation; the abstract calls for comparative studies with and; industry involvement.

    PMID 41240206

  3. Skin effect
    Cosmetic benefit of a biomimetic lamellar cream formulation on barrier function or the appearance of fine lines and wrinkles in randomized proof-of-concept clinical studies

    In 72 women with visible signs of ageing, a niacinamide-containing biomimetic lamellar cream significantly improved the Cutometer R5 elasticity parameter, wrinkle score, TEWL and corneometer values over 4 weeks compared against the untreated side.

    Human trial · 2019 · 72 people · women with visible signs of ageing (Study 2) · Women with visible signs of ageing, applying the cream twice daily for 4 weeks. · Grading of high-resolution images failed to detect improvements in skin texture; proof-of-concept studies.

    PMID 30414275

  4. Skin effect
    A Novel Dermocosmetic Routine Containing Vitamin B3 and 2-Mercaptonicotinyl Glycine Significantly Improves Melasma After 3 Months of Daily Use

    In 91 women with melasma, a skincare routine containing vitamin B3 (niacinamide) and 2-mercaptonicotinyl glycine significantly reduced MASI after 3 months, with roughly 38-41% reduction by 6 months.

    Human trial · 2025 · 91 people · women with melasma · Women aged about 44 with melasma, phototypes III-IV, using the routine twice daily with daily SPF50+ sunscreen. · A clinically relevant difference favoured Kligman's triple combination in the first 3 months; industry-funded; skin radiance and fine wrinkles also improved.

    PMID 41036635

  5. Skin effect
    Niacinamide-containing facial moisturizer improves skin barrier and benefits subjects with rosacea

    A facial moisturiser containing niacinamide improved stratum corneum barrier function and skin hydration, measured instrumentally, in people with rosacea over four weeks of twice-daily use.

    Human trial · 2005 · 50 people · Adults with rosacea · A leave-on facial moisturiser, applied twice daily for four weeks, in adults with rosacea. · The tested article was a finished moisturiser. Fifty participants, one centre, four weeks. The study measured barrier function and hydration.

    PMID 16209160